Rosangela Prizzi

Learn More
BACKGROUND Men have higher rates of osteoporosis and suffer fragility fractures more often than previously believed. Fracture-related morbidity and mortality in men is substantially higher than in women. OBJECTIVE To investigate alendronate for treating osteoporosis in men. METHODS Search limited to 'men' and 'English'; keywords were 'osteoporosis' or(More)
UNLABELLED In a randomized controlled study, we investigated the effect of treatment with intravenous neridronate in prepubertal children with OI. Our study suggests that quarterly intravenous infusions of the bisphosphonate significantly raise the rate of increase in BMD at both the spine and hip, the projected area of the lumbar vertebrae, and height.(More)
Bisphosphonates have been used with success in the treatment of osteoporosis, but oral therapy often lacks compliance. Here we report the results of clinical trial with aminobisphosphonate neridronate administered intravenously (i.v.). The study included 78 postmenopausal women with spine bone mineral density (BMD) at least -2.5 SD below peak. Patients were(More)
UNLABELLED Neridronate therapy in adult patients with OI significantly increases the cross-sectional area of the proximal radius. This observation may provide an additional explanation for the antifracture efficacy of bisphosphonates. INTRODUCTION Bisphosphonate therapy decreases by 70-90% the fracture risk in patients with osteogenesis imperfecta (OI).(More)
  • 1